The United States Department of Defense has granted USD71m to INOVIO (NASDAQ:INO), a United States-based biotechnology company, in order to support the mass production of the firm's CELLECTRA 3PSP smart device and the procurement of CELLECTRA 2000 devices that are used to deliver INO-4800 directly into the skin, it was reported on Tuesday.
INO-4800 is INOVIO's DNA vaccine candidate being developed to protect against the novel coronavirus SARS-CoV-2, which causes COVID-19. CELLECTRA 3PSP is a device that runs on 'AA' batteries and can be stockpiled in large quantities without maintenance. The device is produced at the company's San Diego device manufacturing facility and it has produced initial quantities of the device.
The company is to reveal interim results of United States Phase one clinical studies of INO-4800 later this month. It is planning a Phase two/three efficacy trial this summer.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma